CSA Medical is a pioneering medical technology company specializing in cryotherapy solutions for patients suffering from chronic obstructive pulmonary disease (COPD) with chronic bronchitis. Operating primarily in the European market, CSA Medical's flagship product, the RejuvenAir System, has been approved for use in Europe following a successful multi-center clinical trial. This innovative system utilizes metered cryospray technology to deliver liquid nitrogen at -196°C to targeted areas within the lungs, effectively freezing damaged cells and promoting a rejuvenative healing process. The treatment is minimally invasive, performed via a bronchoscopic procedure, and has shown significant improvements in patient-reported quality of life for up to 12 months post-treatment. CSA Medical's business model focuses on the development and commercialization of advanced medical devices, generating revenue through the sale and licensing of its proprietary technologies. The company serves healthcare providers and patients in the respiratory care market, aiming to address unmet medical needs with cutting-edge solutions.

Keywords: cryotherapy, COPD, chronic bronchitis, RejuvenAir, liquid nitrogen, metered cryospray, bronchoscopic procedure, respiratory care, medical technology, patient quality of life.